ArticleScientific reports2026
Impaired lung function is associated with elevated blood biomarkers of AD/ADRD: unraveling the interplay with risk of dementia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
- Update of
Authors and funding
7 authors.
Funding
Abstract
Background and Objectives: Impaired lung function (ILF) has been associated with cognitive decline and dementia risk in multiple cohorts, yet the role of circulating Alzheimer disease (AD) biomarkers in this relationship is not well understood. We aimed to assess the associations of ILF with AD-related blood biomarkers and to evaluate whether these biomarkers statistically accounted for part of the observed association between ILF and incident dementia. Methods: Serum p-Tau181 and plasma Aβ42/40, NfL, and GFAP were measured in 4,072 participants (mean age 66 ± 10 years; 59% women) in the 2016 Health and Retirement Study. Peak Expiratory Flow (PEF) was assessed in 2012/2014, and cognitive function was measured at four time points between 2014 and 2020 (every two years) to determine dementia status. ILF was defined as predicted PEF < 80%. Multivariable regression examined associations between ILF and AD biomarkers. Mediation models were used to evaluate the extent to which biomarkers statistically accounted for the association between ILF and incident dementia. Results: In total, 881 (21.6%) participants had ILF and 272 (6.8%) participants developed dementia. After adjusting for demographics, education, BMI, smoking, comorbidities, inflammation, eGFR and APOE e4, ILF was associated with a higher risk of dementia (HR = 1.74; 95% CI (1.34, 2.25)). Individuals with ILF had 0.10 SD higher NfL (SE = 0.03; p = 0.004) and 0.09 SD higher p-Tau 181 (SE = 0.03; p = 0.002) compared to those without ILF. In mediation models, higher NfL and p Tau181 accounted for modest proportions of the observed association between ILF and incident dementia, with estimated mediated proportions of 7.3% for NfL and 4.9% for p Tau181. Discussion: ILF was associated with higher levels of blood biomarkers reflecting neurodegeneration and with increased risk of dementia. NfL and p-Tau181 accounted for modest proportions of this association in mediation analyses, suggesting a limited and exploratory contribution. These findings support further investigation into biological pathways linking lung function and cognitive decline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.